21 completed, 4 recruiting, 4 terminated, 4 unknown. 36 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 21, Recruiting 4, Terminated 4, Unknown 4, Not yet recruiting 3 |
| Phase 1 | 5 | Completed 4, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Major Depression: new trials by email Literature Review of Major Depression trials Research Report on Major Depression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin for Depression in Veterans Psilocybin, modafinil, zolpidem - Major Depression | Phase 2 | Not yet recruiting | VA Office of Research and Development | 150 | 2027-01-01 | 2026-10-26 |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback - PTSD, PTSD - Post Traumatic Stress Disorder | Phase 2 | Not yet recruiting | University of New Mexico | 150 | 2026-12-31 | 2026-10-30 |
| Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder Sham iTBS, TMS, D-cycloserine - Major Depression, Healthy Participants | Phase 1 / Phase 2 | Recruiting | Mclean Hospital | 100 | 2026-10-01 | 2026-10-30 |
| Inhaled DMT for Major Depressive Disorder N,N-Dimethyltryptamine (15 mg + 60 mg), N,N-Dimethyltryptamine (1 mg + 4 mg) - MDD, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Universidade Federal do Rio Grande do Norte | 140 | 2026-08-01 | 2026-07-13 |
| Study of Psilocybin Under Anesthesia Controlled by EEG Psilocybin (Usona Institute), Propofol, Placebo - Major Depression | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-07-01 | 2026-05-06 |
| Leucine in Midlife Depression L-leucine, L-lysine - Major Depression | Phase 2 | Recruiting | Emory University | 75 | 2025-02-01 | 2026-09-11 |
| Technology Enhanced Family Treatment Family-Focused Treatment with MCC App - Mood Disorders, Bipolar Disorder | Phase 1 / Phase 2 | Completed | University of California, Los Angeles | 65 | 2018-11-15 | 2024-05-28 |
| A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder SAGE-217, Placebo - Major Depression | Phase 2 | Completed | Biogen | 102 | 2016-12-07 | 2023-11-28 |
| Epidural Stimulation for Resistant Depression Treatment Epidural Electrode - Major Depression | Phase 2 | Unknown | University of Brasilia | 10 | 2016-04-01 | 2017-05-23 |
| Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder AV 101 (4-Chlorokynurenine), Placebo Comparator - Major Depression | Phase 2 | Completed | National Institute of Mental Health (NIMH) | 22 | 2015-10-14 | 2022-04-11 |
| Ketamine Alcohol (in Treatment-Resistant Depression) Ketamine - Magnetic Resonance Imaging, Major Depression | Phase 2 | Recruiting | Mark Niciu | 60 | 2014-04-23 | 2026-05-01 |
| Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression Ayahuasca, placebo - Major Depression | Phase 1 / Phase 2 | Completed | Universidade Federal do Rio Grande do Norte | 35 | 2014-02-01 | 2025-04-06 |
| Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression Deep Brain Stimulation with Activa PC Multi-program Neurostimulator - Major Depression | Phase 2 | Completed | University Hospital, Bonn | 16 | 2013-07-01 | 2018-08-07 |
| Omega 3 FA Supplements as Augmentation in the Treatment of Depression Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement) - Major Depression, Cancer | Phase 2 / Phase 3 | Terminated | UConn Health | 6 | 2013-02-01 | 2017-12-27 |
| Trial of Transcranial Direct Current Stimulation (tDCS) for Depression tDCS (Eldith DC-Stimulator (CE certified)) - Major Depression | Phase 2 | Completed | The University of New South Wales | 3 | 2010-12-01 | 2015-09-17 |
| Open Pilot Trial of TES for Depression tDCS (Eldith DC-Stimulator (CE certified)) - Major Depression | Phase 2 | Completed | The University of New South Wales | 7 | 2010-09-01 | 2015-12-02 |
| Study of Depression-Ketamine-Brain Function Ketamine - Major Depression | Phase 2 | Terminated | Markus KOSEL | 10 | 2010-06-01 | 2015-12-07 |
| Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions Escitalopram, Placebo - TBI, Major Depression | Phase 2 | Completed | Johns Hopkins University | 16 | 2010-04-01 | 2016-10-24 |
| Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS) - Major Depression | Phase 2 / Phase 3 | Completed | University Hospital Tuebingen | 32 | 2010-04-01 | 2013-07-16 |
| Computerized Information-Processing Bias Retraining in Depressed Adolescents Computerized Information-Processing Bias Retraining, Attention Control Training - Major Depression | Phase 2 | Completed | Massachusetts General Hospital | 48 | 2010-03-01 | 2012-05-03 |
Showing 20 of 36. Sign in to see all of them.
Depressive Disorder, Major (36) · Depression (16) · Mood Disorders (5) · Dysthymic Disorder (3) · Bipolar Disorder (2) · Depressive Disorder (2) · Suicidal Ideation (2) · Alcoholism (1) · Anxiety Disorders (1) · Behavior (1) · Cardiovascular Diseases (1) · Combat Disorders (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Hypertension (1)
Mental Disorders (36) · Depressive Disorder (34) · Mood Disorders (31) · Behavioral Symptoms (18) · Behavior (17) · Bipolar and Related Disorders (2) · Self-Injurious Behavior (2) · Vascular Diseases (2) · Alcohol-Related Disorders (1) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Coronary Disease (1) · Endocrine System Diseases (1)
Transcranial Magnetic Stimulation (4) · Escitalopram (3) · Psilocybin (3) · Transcranial Direct Current Stimulation (3) · Docosahexaenoic Acids (2) · Fatty Acids, Omega-3 (2) · Fluoxetine (2) · Ketamine (2) · 1,2-benzisothiazol-3(2H)-one, 2-(4-(4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl)butyl)-, 1,1-dioxide (1) · 4-chlorokynurenine (1) · Citalopram (1) · Cycloserine (1) · Deep Brain Stimulation (1) · Desipramine (1) · Desvenlafaxine Succinate (1)
The University of New South Wales (5) · National Institute of Mental Health (NIMH) (2) · Universidade Federal do Rio Grande do Norte (2) · Affectis Pharmaceuticals AG (1) · BeerYaakov Mental Health Center (1) · Biogen (1) · China Medical University Hospital (1) · Emory University (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Hadassah Medical Organization (1) · Helse Stavanger HF (1) · Johns Hopkins University (1) · Mark Niciu (1) · Markus KOSEL (1) · Massachusetts General Hospital (1)
United States (15) · Australia (5) · Germany (4) · Brazil (3) · Israel (3) · Belgium (2) · Austria (1) · Canada (1) · Chile (1) · Czechia (1) · Estonia (1) · Finland (1) · France (1) · Netherlands (1) · Norway (1)
Carlos A Zarate, M.D. (2) · Gordon B Parker, Dsc MD PhD (2) · Anne Marie Rees, BSc MBBS (1) · Armen Arevian, MD (1) · Chieh-Liang Huang, MD (1) · Colleen Loo, MBBS (1) · Colleen Loo, MBBS, FRANZCP, MD (1) · David J Miklowitz, PhD (1) · Davin Quinn, MD (1) · Dolors Puigdemont, MD (1) · Dr. Boris Heifets, MD, PhD (1) · Draulio B de Araujo, Ph.D (1) · Ebrahim Haroon, MD (1) · Ehud Klein, MD (1)
PMID 34817851, PMID 42171126, PMID 15365580, PMID 18061147, PMID 19414708, PMID 22050051, PMID 23562005, PMID 25220861, PMID 29903051, PMID 30253883, PMID 31231276, PMID 31798447, PMID 32236521, PMID 33128939, PMID 33360365, PMID 34510411, PMID 35378149, PMID 38094620, PMID 40109484, PMID 40494497, PMID 41257792, PMID 41743330, PMID 42498781, PMID 42521762
2009 (1), R00AA024142 (1), R01MH132059 (1), R34MH117200 (1)